Literature DB >> 21727124

The evolving biology of cell reprogramming.

Ian Wilmut1, Gareth Sullivan, Ian Chambers.   

Abstract

Modern stem cell biology has achieved a transformation that was thought by many to be every bit as unattainable as the ancient alchemists' dream of transforming base metals into gold. Exciting opportunities arise from the process known as 'cellular reprogramming' in which cells can be reliably changed from one tissue type to another. This is enabling novel approaches to more deeply investigate the fundamental basis of cell identity. In addition, new opportunities have also been created to study (perhaps even to treat) human genetic and degenerative diseases. Specific cell types that are affected in inherited disease can now be generated from easily accessible cells from the patient and compared with equivalent cells from healthy donors. The differences in cellular phenotype between the two may then be identified, and assays developed to establish therapies that prevent the development or progression of disease symptoms. Cellular reprogramming also has the potential to create new cells to replace those whose death or dysfunction causes disease symptoms. For patients suffering from inherited cases of degenerative diseases like Parkinson's disease or amyotrophic lateral sclerosis (also known as motor neuron disease), the future realization of such cell-based therapies would truly be worth its weight in gold. However, before this enormous potential can become a reality, several significant biological and technical challenges must be overcome. Furthermore, to maintain the credibility of the scientific community with the general public, it is important that hope-inspiring advances are not over-hyped. The papers in this issue of the Philosophical Transactions of the Royal Society B: Biological Sciences cover many areas relevant to this topic. In this Introduction, we provide an overall context in which to consider these individual papers.

Entities:  

Mesh:

Year:  2011        PMID: 21727124      PMCID: PMC3130426          DOI: 10.1098/rstb.2011.0051

Source DB:  PubMed          Journal:  Philos Trans R Soc Lond B Biol Sci        ISSN: 0962-8436            Impact factor:   6.237


  155 in total

1.  A novel locus for late onset amyotrophic lateral sclerosis/motor neurone disease variant at 20q13.

Authors:  A L Nishimura; M Mitne-Neto; H C A Silva; J R M Oliveira; M Vainzof; M Zatz
Journal:  J Med Genet       Date:  2004-04       Impact factor: 6.318

2.  Embryonic germ cells induce epigenetic reprogramming of somatic nucleus in hybrid cells.

Authors:  M Tada; T Tada; L Lefebvre; S C Barton; M A Surani
Journal:  EMBO J       Date:  1997-11-03       Impact factor: 11.598

Review 3.  Induced pluripotent stem cells: opportunities and challenges.

Authors:  Keisuke Okita; Shinya Yamanaka
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2011-08-12       Impact factor: 6.237

4.  A genome-wide RNAi screen reveals determinants of human embryonic stem cell identity.

Authors:  Na-Yu Chia; Yun-Shen Chan; Bo Feng; Xinyi Lu; Yuriy L Orlov; Dimitri Moreau; Pankaj Kumar; Lin Yang; Jianming Jiang; Mei-Sheng Lau; Mikael Huss; Boon-Seng Soh; Petra Kraus; Pin Li; Thomas Lufkin; Bing Lim; Neil D Clarke; Frederic Bard; Huck-Hui Ng
Journal:  Nature       Date:  2010-10-17       Impact factor: 49.962

5.  Induced pluripotent stem cells generated without viral integration.

Authors:  Matthias Stadtfeld; Masaki Nagaya; Jochen Utikal; Gordon Weir; Konrad Hochedlinger
Journal:  Science       Date:  2008-09-25       Impact factor: 47.728

6.  VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death.

Authors:  Diether Lambrechts; Erik Storkebaum; Masafumi Morimoto; Jurgen Del-Favero; Frederik Desmet; Stefan L Marklund; Sabine Wyns; Vincent Thijs; Jörgen Andersson; Ingrid van Marion; Ammar Al-Chalabi; Stephanie Bornes; Rhiannon Musson; Valerie Hansen; Lars Beckman; Rolf Adolfsson; Hardev Singh Pall; Hervé Prats; Severine Vermeire; Paul Rutgeerts; Shigehiro Katayama; Takuya Awata; Nigel Leigh; Loïc Lang-Lazdunski; Mieke Dewerchin; Christopher Shaw; Lieve Moons; Robert Vlietinck; Karen E Morrison; Wim Robberecht; Christine Van Broeckhoven; Désiré Collen; Peter M Andersen; Peter Carmeliet
Journal:  Nat Genet       Date:  2003-08       Impact factor: 38.330

7.  Reprogramming of human somatic cells to pluripotency with defined factors.

Authors:  In-Hyun Park; Rui Zhao; Jason A West; Akiko Yabuuchi; Hongguang Huo; Tan A Ince; Paul H Lerou; M William Lensch; George Q Daley
Journal:  Nature       Date:  2007-12-23       Impact factor: 49.962

8.  Clinical characteristics of a family with chromosome 17-linked disinhibition-dementia-parkinsonism-amyotrophy complex.

Authors:  T Lynch; M Sano; K S Marder; K L Bell; N L Foster; R F Defendini; A A Sima; C Keohane; T G Nygaard; S Fahn
Journal:  Neurology       Date:  1994-10       Impact factor: 9.910

9.  Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs.

Authors:  Gabsang Lee; Eirini P Papapetrou; Hyesoo Kim; Stuart M Chambers; Mark J Tomishima; Christopher A Fasano; Yosif M Ganat; Jayanthi Menon; Fumiko Shimizu; Agnes Viale; Viviane Tabar; Michel Sadelain; Lorenz Studer
Journal:  Nature       Date:  2009-08-19       Impact factor: 49.962

10.  Direct cell reprogramming is a stochastic process amenable to acceleration.

Authors:  Jacob Hanna; Krishanu Saha; Bernardo Pando; Jeroen van Zon; Christopher J Lengner; Menno P Creyghton; Alexander van Oudenaarden; Rudolf Jaenisch
Journal:  Nature       Date:  2009-11-08       Impact factor: 49.962

View more
  7 in total

Review 1.  A role for polyamine regulators in ESC self-renewal.

Authors:  Tianyun Zhao; Kim Jee Goh; Huck Hui Ng; Leah A Vardy
Journal:  Cell Cycle       Date:  2012-11-19       Impact factor: 4.534

2.  Probing into the biological processes influenced by ESC factor and oncoprotein HMGA2 using iPSCs.

Authors:  Amir Morshedi; Zhonglu Ren; Jinming Li; Peter Dröge
Journal:  Stem Cell Rev Rep       Date:  2013-08       Impact factor: 5.739

Review 3.  Modelling human disease with pluripotent stem cells.

Authors:  Richard Siller; Sebastian Greenhough; In-Hyun Park; Gareth J Sullivan
Journal:  Curr Gene Ther       Date:  2013-04       Impact factor: 4.391

Review 4.  'Hearts and bones': the ups and downs of 'plasticity' in stem cell biology.

Authors:  Paola Bonfanti; Yann Barrandon; Giulio Cossu
Journal:  EMBO Mol Med       Date:  2012-03-02       Impact factor: 12.137

Review 5.  Stem Cell Therapy: A New Treatment for Burns?

Authors:  Anna Arno; Alexandra H Smith; Patrick H Blit; Mohammed Al Shehab; Gerd G Gauglitz; Marc G Jeschke
Journal:  Pharmaceuticals (Basel)       Date:  2011-10-21

6.  A stochastic model dissects cell states in biological transition processes.

Authors:  Jonathan W Armond; Krishanu Saha; Anas A Rana; Chris J Oates; Rudolf Jaenisch; Mario Nicodemi; Sach Mukherjee
Journal:  Sci Rep       Date:  2014-01-17       Impact factor: 4.379

7.  High-Fidelity Reprogrammed Human IPSCs Have a High Efficacy of DNA Repair and Resemble hESCs in Their MYC Transcriptional Signature.

Authors:  Pratik K Nagaria; Carine Robert; Tea Soon Park; Jeffrey S Huo; Elias T Zambidis; Feyruz V Rassool
Journal:  Stem Cells Int       Date:  2016-09-01       Impact factor: 5.443

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.